"The ultimate goal of the company is to be the therapeutic leader by best understanding the science and further improving on the types of therapies we have today," he said. "The types of product candidates we have can not only dramatically help patients — they can also help save money."
Juno shares were down by more than 50 percent in 2016 after the company halted a clinical trial in November 2016.
Bishop commented on the trial halt, competition and long-term strategy of the company.
To watch the interview in its entirety, you must be a CNBC PRO subscriber.